The cellular and molecular mechanisms controlling growth in the vascular wall will be studied using a concerted ultrastructural, pharmacological, and biochemical approach. The regulation of cell growth in large blood vessels plays a key role in a number of important physiological and pathological processes, and thus represents a potential control point for diseases such as atherosclerosis and thrombosis. Data has been generated in vivo and in vitro which strongly indicates that endothelial cells function as important regulators of smooth muscle cell growth, and that heparin may play a critical role in the vessel wall as a regulator of smooth muscle cell proliferation. Evidence has also been obtained which implicates macrophages as possible mediators of injury to the vascular wall. The role of heparin binding and internalization in the growth inhibitory action of heparin will be examined. Heparin will be localized intracellularly using a variety of ultrastructural and cytochemical techniques. Based on preliminary experiments, the effect of heparin on several processes thought to be important in the stimulation of cell growth will be determined: uptake of nutrients and growth factors, recycling of ligands and receptors, stimulation of specific protein kinases, and organellar movement. The role of macrophages in vascular injury will be studied by measuring the adherence, superoxide production, and killing effect on endothelial and smooth muscle cells by macrophages from normo- and hypercholesterolemic rats. Membrane changes will be assayed biochemically and biophysically. The hypothesis that the endothelim is moving continuously towards regions of blood vessels which experience high shear forces and thus may have high injury rates, ie towards the heart, will be tested. This will be done by combining in vivo endothelial labeling techniques with microsurgery.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL017747-13
Application #
3335424
Study Section
Pathology A Study Section (PTHA)
Project Start
1979-06-01
Project End
1989-05-31
Budget Start
1987-06-01
Budget End
1988-05-31
Support Year
13
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
Schools of Medicine
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Fan, Wen-Hua; Karnovsky, Morris J (2002) Increased MMP-2 expression in connective tissue growth factor over-expression vascular smooth muscle cells. J Biol Chem 277:9800-5
Fan, W H; Karnovsky, M J (2000) Activation of protein kinase C inhibits the expression of connective tissue growth factor. Biochem Biophys Res Commun 275:312-21
Fan, W H; Pech, M; Karnovsky, M J (2000) Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro. Eur J Cell Biol 79:915-23
Edelman, E R; Nathan, A; Katada, M et al. (2000) Perivascular graft heparin delivery using biodegradable polymer wraps. Biomaterials 21:2279-86
San Antonio, J D; Verrecchio, A; Pukac, L A (1998) Heparin sensitive and resistant vascular smooth muscle cells: biology and role in restenosis. Connect Tissue Res 37:87-103
Pukac, L; Huangpu, J; Karnovsky, M J (1998) Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration. Exp Cell Res 242:548-60
Pukac, L A; Carter, J E; Ottlinger, M E et al. (1997) Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells. J Cell Physiol 172:69-78
Pukac, L A; Carter, J E; Morrison, K S et al. (1997) Enhancement of diaminobenzidine colorimetric signal in immunoblotting. Biotechniques 23:385-8
Rogers, C; Welt, F G; Karnovsky, M J et al. (1996) Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 16:1312-8
Shin, Y T; Adams, D H; Wyner, L R et al. (1995) Intrathymic tolerance in the Lewis-to-F344 chronic cardiac allograft rejection model. Transplantation 59:1647-53

Showing the most recent 10 out of 60 publications